Anti-inflammation therapy by activation of prostaglandin EP4 receptor in cardiovascular and other inflammatory diseases

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 2, 2012, Pages 116-123

  Tang, Eva H C ^a   Libby, Peter ^b   Vanhoutte, Paul M ^a   Xu, Aimin ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

aneurysms; anti inflammation; atherosclerosis; cardiovascular diseases; chemokines; EP4; inflammation; macrophages; prostaglandin E receptor; prostaglandin E2; prostanoids; T lymphocytes

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; INTERLEUKIN 12; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTANOID; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; ANEURYSM; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; ATHEROSCLEROSIS; BONE MARROW CELL; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; COLITIS; CONFERENCE PAPER; CYTOKINE RELEASE; ENCEPHALOMYELITIS; GENE EXPRESSION; GRAFT SURVIVAL; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; STOMACH ULCER; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGES; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; T-LYMPHOCYTES;

EID: 84857053651     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182244a12     Document Type: Conference Paper

References (51)

1. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007;50:470-479. (Pubitemid 350146448)
2. Amer M, Bead VR, Bathon J, et al. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease-a cautionary tale. Cardiol Rev. 2010;18:204-212.
3. Fries JF. Selective cyclooxygenase inhibition: promise for future NSAID therapy? Scand J Rheumatol Suppl. 1996;102:23-28.
4. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959. (Pubitemid 33010342)
5. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634-1642. (Pubitemid 46648649)
6. Holmes DR, Wester W, Thompson RW, et al. Prostaglandin E2 synthesis nand cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg. 1999;25:810-815.
7. Giuliano F, Warner TD. Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Exp Therap. 2002;302:1001-1006. (Pubitemid 35424382)
8. Yamane H, Sugimoto Y, Tanaka S, et al. Prostaglandin E2 receptors, EP2 and EP4, differentially modulate TNF-a and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem Biophy Res Commun. 2000;278:224-228.
9. Nataraj C, Thomas DW, Tilley SL, et al. Receptors for prostaglandin E2 that regulate cellular immune response in the mouse. J Clin Invest. 2001; 108:1229-1235. (Pubitemid 32995382)
10. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002;109;883-893. (Pubitemid 34275109)
11. Sakamoto A, Matsumur J, Mii S, et al. A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production. Shock. 2004;22:76-81. (Pubitemid 40228214)
12. Takayama K, Garcia-Cardena G, Sukhova GK, et al. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem. 2002;277:44147-44154. (Pubitemid 36157844)
13. Takayama K, Sukhova GK, Chin MT, et al. A novel prostaglandin E receptor 4-associated protein participates in anti-inflammatory signaling. Circ Res. 2006;98:499-504.
14. Hishikari K, Suzuki J, Ogawa M, et al. Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res. 2009;81:123-132.
15. Jiang GL, Im WB, Donde Y, et al. EP4 agonist alleviates indomethacininduced gastric lesions and promotes chronic gastric ulcer healing. World J Gastroenterol. 2009;15:5149-5156.
16. Ogawa M, Suzuki J, Kosuge H, et al. The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation. 2009;87:1645-1653.
17. Scher JU, Pillinger MH. The anti-inflammatory effects of prostaglandins. J Investig Med. 2009;57:703-308.
18. Shi J, Johansson J,Woodling NS, et al. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol. 2010;184:7207-7218.
19. Tang EH, Shimizu K, Christen T, et al. Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions. Cardiovasc Res. 2010; doi:10.1093/cvr/cvq262.
20. Tang EHC, Shvartz E, Shimizu K, et al. Deletion of EP4 on bone marrowderived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2010; doi: 10.1161/ATVBAHA.110.216580.
21. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev. 2007;59:207-224. (Pubitemid 47481434)
22. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007; 282:11613-11617. (Pubitemid 47100657)
23. Hwang D. Fatty acids and immune responses-a new perspective in searching for clues to mechanism. Annu Rev Nutr. 2000;20:431-456.
24. Minami M, Shimizu K, Okamoto Y, et al. Prostaglandin E2 receptor type 4-associated protein interacts directly with NK-kB1 and attenuates macrophage activation. J Biol Chem. 2007;15:9692-9703.
25. Zhong WW, Burke PA, Drotar BME, et al. Effects of prostaglandin E2, cholera toxin and 8-bromo-cyclic AMP on lipopolysaccharide-induced gene expression of cytokines in human macrophages. Immmunology. 1995;84:446-452.
26. van der Pouw Kraan TC, Boeije LC, Smeenk RJ, et al. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med. 1995; 181:775-779.
27. Hilkens C, Snijders A, Vermeulen H, et al. Accessory cell-derived interleukin-12 and prostaglandin E2 determine the level of interferongamma produced by activated human CD4+ T cells. Ann N Y Acad Sci. 1996;795:349-350. (Pubitemid 27029588)
28. Nomi T, Sho M, Akahori T, et al. Protective effect of prostaglandin E2 receptor EP2 and EP4 in alloimmune response in vivo. Transplant Proc. 2006;38:3209-3210.
29. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 1991;146:108-113.
30. Gold KN, Weyand CM, Goronzy JJ. Modulation of helper T cell function by prostaglandins. Arthritis Rheum. 1994;37:925-933. (Pubitemid 24184547)
31. Hilkens CM, Vermeulen H, van Neerven RJ, et al. Differential modulation of T helper 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol. 1995;25:59-63.
32. Leung KH, Mihich E. Prostaglandin modulation of development of cellmediated immunity in culture. Nature. 1980;288:597-600. (Pubitemid 11223692)
33. Hendricks A, Leibold W, Kaever V, et al. Prostaglandin E2 is variably induced by bacterial superantigens in bovine mononuclear cells and has a regulatory role for the T cell proliferative response. Immunobiology. 2000;201:493-505. (Pubitemid 30242917)
34. Mastino A, Piacentini M, Grelli S, et al. Induction of apoptosis in thymocytes by prostaglandin E2 in vivo. Dev Immunol. 1992;2:263-271.
35. Pica F, Franzese O, D'Onofrio C, et al. Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2 independent associated pathway. J Pharmacol Exp Ther. 1996; 277:1793-1800. (Pubitemid 27167200)
36. Ganapathy V, Gurlo T, Jarstadmarken HO, et al. Regulation of TCRinduced IFN-gamma release from islet-reactive non-obese diabetic CD8(+) T cells by prostaglandin E(2) receptor signaling. Int Immunol. 2000;12:851-860. (Pubitemid 30410458)
37. Goetzl EJ, An S, Zeng L. Specific suppression by prostaglandin E2 of activation-induced apoptosis of human CD4+CD8+ T lymphoblasts. J Immunol. 1995;154:1041-1047.
38. Katamura K, Shintaku N, Yamauchi Y, et al. Prostaglandin E2 at priming of naiv̈e CD4+ T cells inhibits acquisition of ability to produce IFNgamma and IL-2, but not IL-4 and IL-5. J Immunol. 1995;155:4604-4612. (Pubitemid 3010794)
39. Wise H. Activation of the prostaglandin EP4-receptor subtype is highly coupled to inhibition of N-formyl-methionyl-leucyl-phenylalanine-stimulated rat neutrophil aggregation. Prostaglandins Leukot Essent Fatty Acids. 1998;58:77-84. (Pubitemid 28053794)
40. Fabricius D, Neubauer M, Mandel B, et al. Prostaglandin E2 inhibits IFNalpha secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J Immunol. 2010;184:677-684.
41. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem. 2005;13:1877-1893.
42. Degousee N, Fazel S, Angoulvant D, et al. Microsomal prostaglandin E2 synthase-1 deletions leads to adverse left ventricular remodeling after myocardial infarction. Circulation. 2008;117:1701-1710. (Pubitemid 351482607)
43. Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213-220.
44. Rolland PH, Jouve R, Pellegrin E, et al. Alteration in prostaglandin and prostaglandin E2 production. Correlation with changes in human aortic atherosclerotic disease. Arteriosclerosis. 1984;4:70-78. (Pubitemid 14222599)
45. Babaev VR, Chew JD, Ding L, et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab. 2008;8:492-501.
46. Bayston T, Ramessur S, Reise J, et al. Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg. 2003;38:354-359. (Pubitemid 41123262)
47. Gitlin JM, Trivedi DB, Langenbach R, et al. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res. 2007;73:227-236. (Pubitemid 44937188)
48. Wang M, Lee E, Song W, et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation. 2008;117:1302-1309. (Pubitemid 351365673)
49. Hacker-Shahin, B, Droge W. Antagonistic regulator of cytotoxic T lymphocyte activation by prostaglandin E2 and l-ornithine. Immunopharmacology. 1986;11:57-60. (Pubitemid 16165685)
50. Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion. Nat Med. 2009;15:633-640.
51. Chen Q, Muramoto K, Masaaki N, et al. A novel antagonist of the prostaglandin E2 EP4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmcol. 2010; 160:292-310.